The homozygous presence of the arginine-16 variant of the β 2 -adrenoceptor gene, ADRB2, reverses the benefits from the regular use of short-acting β 2 -agonists in asthmatic adults as compared to the homozygous glycine-16 genotype. We studied the effect of this polymorphic variation on asthma exacerbations in children and young adults, and its relation to long-acting β 2 -agonists. Method Cross-sectional survey using electronic records, direct interviews, genotype determination of position 16 and 27 of the ADRB2 gene in DNA from mouthwash samples for 546 children and young asthmatics attending paediatric and young adult asthma clinics in Tayside, Scotland over 2004-5. The primary outcome measure was asthma exacerbations over the previous 6 months.
Introduction
Asthma is one of the most common chronic diseases in the world 1 2 . Scotland tops the ranking list by country for the prevalence of current asthma symptoms in the childhood and teenage years 3 . The guidelines by the Scottish Intercollegiate Guidelines Network/ British Thoracic Society 4 and the guidance for best practice in the United States 5 recommends add-on therapy with an inhaled long-acting β 2 -agonist (LABA) such as salmeterol in children with asthma when symptoms are not controlled on inhaled short-acting β 2 -agonists according to need together with regular inhaled steroids. A number of polymorphisms in the gene encoding the human β 2 -adrenergic receptor have been known to alter its function in the cardiovascular and respiratory systems. In blood vessels, where β 2 -adrenergic receptors mediate vasodilatation, the Arg/Arg polymorphism at position 16 of the β 2 -receptor is associated with enhanced agonistmediated desensitization in the vasculature, while the Glu27 polymorphism is associated with increased agonist-mediated responsiveness 6 . In the airway, the presence of the homozygous Arg/Arg genotype (about 15% of patients with asthma in the US 7 and UK 8 ) confers relative protection against down-regulation by endogenous catecholamines and reverses the benefits from the regular use of short and long acting β 2 -agonists in adults [7] [8] [9] . The presence of the Arg-16 polymorphism (either Arg/Arg or Arg/Gly) confers bronchoprotective subsensitivity to methacholine and adenosine monophosphate challenge in steroid treated adults with asthma treated with formoterol and salmeterol 8 . However, the consequences of real-life prescribing of LABA, as an add-on medication to inhaled steroids, in Arg/Arg and Arg/Gly individuals, have not been explored. In addition, although a significant heterogeneity in bronchoprotection with salmeterol has been described, particularly in children with asthma 10 , it is not known if polymorphisms in the human β 2 -adrenergic receptor gene ADRB2 could contribute to this variation. In children with asthma, school absences from asthma 11 , use of short courses of oral steroids 12 and asthma-related hospital admissions 13 represent well-validated measures of asthma exacerbations. In this manuscript we have tested the hypothesis that the Arg16 variant status increases the likelihood of asthma exacerbations in children and young people with asthma and have explored the relationship between the Arg16 genotype and exacerbations in the context of "real life" prescribing of the short and long-acting β 2 -agonists, salbutamol and salmeterol.
Methods
We collected information on demographic, anthropometric, clinical details and β 2 -receptor genotype in children with physician-diagnosed asthma attending primary and secondary clinics in 12 primary care practices and a secondary care asthma clinic in Tayside in 2004-5 (n=546) . A DNA sample was collected by mouthwash after informed consent was given by the patient and the parent/guardian. The study was approved by the Tayside Committee on Medical Research Ethics. DNA was prepared using the Qiagen Dneasy 96 kit, and genotypes were determined using Taqman-based allelic discrimination assays on an ABI 7700 sequence detection system 14 . For the Gly16Arg variant the following probes and primers were used: Forward primer-GAACGGCAGCGCCTTCT, Reverse primer-GCACATTGCCAAACACGATG, Arg16 probe-Cal Orange-CACCCAATAGAAGCCATGCGCCGGACCACGAC-BHQ, Gly16 probe-FAM-CACCCAATGGAAGCCATGCGCCGGACCACGAC-BHQ. For the Glu27Gln variant, the forward primer was identical to the forward primer for the Gly16Arg variant and the reverse primer-TGAGAGACATGACGATGCCC. Gln27 probe-Cal Orange-CCATGCGCCGGACCACGACGTCACGCAGCAAAGGGACGA-BHQ Glu27 probe-FAM-CCATGCGCCGGACCACGACGTCACGCAGGAAAGGGACGA-BHQ. We defined a population taking regular inhaled salmeterol 50 micrograms twice daily (n=164) and a cohort not taking salmeterol (n= 382). We also defined the population according to their step of treatment consistent with the British Thoracic Society (BTS) guidelines (step 1 = inhaled β 2 -agonists alone; step 2 = step 1 plus inhaled steroids; step 3 = step 2 plus inhaled long-acting β 2 agonists; step 4 = step 3 plus montelukast) 4 (table 1). The inhaled β 2 -agonist use profile for the population was as follows: 351 participants on inhaled salbutamol as required, 31 on regular inhaled salbutamol, 2 on regular salbutamol without any inhaled steroids and 164 on regular inhaled salmeterol with inhaled steroids. Any asthma-related absence from school, short courses of oral steroids and asthmarelated hospital admissions over the previous 6 months were recorded by parental recall for the children less than 16 years, and by the participants themselves if aged 16 years and above. For simplicity and greater accuracy through recall, only yes/no responses for any of the three options were used for the analysis. Binary logistic regression was used to calculate odds ratios and p values for asthma exacerbations. In the comparisons of homozygotes as has been previously examined (7), Gly/Gly16 was coded = 0 and Arg16Arg16 coded = 1. For the co-dominant model 0= Gly/Gly16, 1= Gly/Arg16, 2= Arg/Arg16. Age, gender and exposure to tobacco smoke were included in all models as covariates. Other potential covariates, such as seasonality, dose of inhaled steroids and frequency of short-acting β 2 -agonist use as rescue medication did not contribute significantly to the model and were not associated with genotype in any subgroup tested, and hence were excluded from the final analysis. All statistical analysis was performed using SPSS version 11. Our primary analysis involved testing the association of the genotype of ADRB2 and exacerbations over all asthma patients on BTS treatment steps 1-4. Our power calculation showed that this analysis had a 99% power to detect an odds ratio of 1.92, and an 80% power to detect an odds ratio of 1.52. We had also planned a number of secondary analyses. As our sample comprised less than 0.5% (n=2) of patients who were being treated with regular inhaled salbutamol without inhaled steroids, we were unable to compare genotypes in these patients due to insufficient numbers. We wished, however, to test the associated risk of possessing the Arg16 polymorphism on asthma exacerbations in asthmatics on long acting β agonists and those not on long acting β agonists. In the population taking salmeterol, we had a 99% power to detect an odds ratio of 2.73 between the Arg/Arg 16 and Gly/Gly 16 homozygotes, and a 80% power to detect an odds ratio of 1.90. In the non salmeterol treated group, we had 80% power to detect an odds ratio of 1.75 in this group, and had 95% power to detect an odds ratio of 2.0.
Results
The population characteristics are presented in table 1. The prevalence of the Arg/Arg16 (15%) and Arg/Gly 16(45%) and Gly/Gly 16 (38%) genotypes in children and young people with asthma within Tayside was similar to that observed for the US and UK populations 7 8 . Table 2 presents the relative distributions of the Arg/Gly polymorphisms on codon 16 and the Gln/Glu polymorphisms on codon 27 for the population. No individuals were observed with the compound diplotype of both Arg/Arg16 and Glu/Glu 27, thus confirming the tight linkage disequilibrium. Arg16Gly or Glu27Gln had no significant effects on baseline pulmonary function (forced expiratory volume in 1 second, forced vital capacity and peak expiratory flow) (data not shown). We tested the association of the genotype of ADRB2 and exacerbations over all BTS treatment steps 1-4, using a simple genetic contrast comprising homozygous genotypes Arg/Arg16 vs Gly/Gly16, as has been previously analysed 7 8 (Table 3 ). This demonstrated a significant overall increased hazard for exacerbations in individuals homozygous for the Arg16 variant: (OR 2.05, 95%CI = 1.19-3.53; p=0.010). When the entire data was examined, including the heterozygotes, the dominant and recessive models did not provide a good fit of the data (data not shown), however the co-dominant model was significant, confirming the intermediate risk posed by the heterozygote grouping (OR 1.32 per genotypic step, 95%CI= 1.03-1.71, p= 0.030). As the co-dominant model provided the best fit of the data this model was used for the remainder of the analysis. As recent studies have shown Arg16 to be associated with worsened lung function on either long acting beta agonists or short acting beta agonists in randomised clinical trials 15 we wished to explore the genotypic risk associated with the four BTS treatment steps . The associated risk of possessing the Arg16 polymorphism was only significant (p=0.023) in asthmatics on BTS step 3 (ie regular inhaled salmeterol plus inhaled steroids with inhaled salbutamol on demand, Table 4 ), with a gene dosage effect of the Arg16 variant in a co-dominant model. This was not significant in the participants on the other BTS steps of treatment-including step 4 (ie. regular inhaled salmeterol plus inhaled steroids plus montelukast with inhaled salbutamol on demand), although the observed hazard in each BTS step was above 1, the current study was underpowered to detect such small effects in these groups. In contrast, the Glu27 polymorphism and the Glu27Gln variant did not show any effect on asthma exacerbations measured as above, either considered in isolation or as a covariate with the Gly16Arg variant (data not shown). The Arg16 variant was associated with a greater frequency of asthma exacerbations in salmeterol treated patients (i.e. steps 3 and 4 combined): this was found to hold true with both the co-dominant model (as shown in Table 5 ), as well as for the homozygote only comparison yielding significant results (Arg/Arg16 vs. Gly/Gly16: OR = 3.40, 95% CI = 1.19-9.40, p = 0.022). The larger group of individuals not on salmeterol also demonstrated an increased hazard for exacerbation, but this did not reach significance (Arg/Arg16 vs. Gly/Gly16: OR = 1.77, 95% CI = 0.91-3.44, p = 0.093). This may be due to a lack of power as we had only 80% power to detect an odd ratio of 1.75 in this group, and only had 95% power to detect an odds ratio of 2.0.
Discussion
The study concludes that there is an increased hazard for exacerbations in young asthmatics homozygous for the Arg16 variant, with a particular effect of regular inhaled salmeterol on this increase in risk. Prospective clinical trials have shown that homozygous presence of the arginine-16 variant of the β 2 -adrenoceptor gene, ADRB2, reverses the benefits from the regular use of short-acting β 2 -agonists in asthmatic adults as compared to the homozygous glycine-16 genotype 7 . We confirm these findings in a population of children and young adults treated across all BTS treatment steps 1-4, which have demonstrated poorer overall control in Arg16 compared to Gly16 homozygotes. The previous observations reported in older adults with asthma carrying the homozygous arginine genotype 7 8 , suggested that prolonged receptor occupancy by a high affinity agonist such as salmeterol, given twice daily, may result in down regulation and impaired receptor coupling. This in turn would lead to subsensitivity of response, and greater asthma exacerbations. This is in keeping with the dynamic kinetic receptor regulation hypothesis as proposed by Liggett, whereby the arginine compared to the glycine genotype would be relatively resistant to down regulation and desensitization by endogenous catecholamines, so that the arginine genotype would be more prone to subsensitivity of response on subsequent exposure to a LABA such as salmeterol 16 . While consistent with this hypothesis, our observations extend the genotypic observations, as less than 0.5% of our patients were treated with regular short acting β 2 -agonists without steroid co-medication, and the primary risk was seen in individuals taking regular long acting beta agonists. This is a predictable phenomenon based on the fact that these individuals will have the most persistently liganded adrenoreceptors compared to other treatment groups. A similar adverse effect of salmeterol on lung function and asthma severity scores in Arg16 homozygote adults has recently been demonstrated 15 . We were particularly interested in testing our hypothesis regarding asthma exacerbations in children and young adults with asthma. This is because salmeterol shows greater heterogeneity of response and seems to be less effective in children than in adults with asthma 10 . We were interested in exploring whether this "lack of efficacy" from genotypic variation was relevant to the practical management of asthma in this population, through an effect on asthma control over a period of several months. Our study involved the cross-sectional collection of data from parental or patient recall and this process may be open to bias. However, although school records are a more accurate source of data on school attendance, they do not specify the cause of the absence. Parental or adolescent recall, the method used for our study, may be more susceptible to bias, but has been shown to be a sensitive measure of school absence caused specifically by asthma 11 . Our data would suggest that the Arg16 genotype may be a clinically important pharmacogenetic paradigm, and that such individuals might gain less benefit from taking regular salmeterol, despite concomitant inhaled steroid administration. An overall increase in asthma exacerbations resulting in increased school absences (table 1) in children with asthma could have important long-term consequences, affecting the social and occupational trajectories of the children in later life 17 . There is evidence, for example, that adults with childhood-onset asthma may experience a significant disadvantage in the labour market 11 . Genetic polymorphic variation in children with asthma may thus worsen the social consequences of this disease through adverse drug response.
It was also noticeable that our patients as expected had well-preserved lung function, with the overall mean FEV 1 being 97%. Thus, the deleterious effect of salmeterol in genetically susceptible patients seems to be unrelated to airway calibre as such, in turn suggesting the adverse effects were possibly more defined by bronchoprotective than bronchodilator subsensitivity, during a period of increased airway tone (i.e. during asthma exacerbations rather than during the quiescent state). This is also suggested by previous work using bronchial challenge in adults with asthma, where the degree of bronchoprotection conferred by long acting β 2 -agonists was less in patients who had the homozygous or heterozygous arginine genotype 8 . However as we did not perform bronchoprovocation challenges in our cohort, we can only suggest this mechanism as a putative hypothesis 18 . It would appear that salmeterol is not beneficial, and that other second line controller medication (e.g. montelukast or theophylline) may be preferable in susceptible patients with the homozygous arginine genotype when inhaled steroids alone fail to control the symptoms of asthma. Indeed it was intriguing to note that there a lower increased risk of excerbations in our homozygous Arg16 patients exposed to regular salmeterol who were also taking montelukast (step 4, table 5), suggesting a possible protective effect of concomitant leukotriene receptor antagonist therapy, however our study does not have sufficient power to detect the difference between these two groups. Our results suggest the need for further prospective randomised controlled trials to address these key questions.
(2378 words) British Thoracic Society step of asthma treatment
Step 1 79 (14.5%)
Step 2 303 (55.5%) Step 3 92 (16.8%) (step 1 = inhaled β 2 -agonists alone; step 2 = step 1 plus inhaled steroids; step 3 = step 2 plus inhaled long-acting β 2 agonists; step 4 = step 3 plus montelukast)
Step 4 72 (13.2%)
Number on inhaled salmeterol
Step 3 Step 4 (Step 3 plus oral montelukast) Total 31 (44%) 41 (57%) 72
1.617 (p=0.249**) ** p values were calculated by binary logistic regression analysis corrected for age, sex and exposure to tobacco smoke using a co-dominant model -ie. a gene dosage effect for the Arg16 variant. Odds ratios are per genotypic step. 
